Isis Pharmaceuticals, Inc. Spinoff Altair Therapeutics Shut Down After Mid-Stage Asthma Study Fails

Xconomy -- San Diego-based Altair Therapeutics, a spinoff from Isis Pharmaceuticals (NASDAQ: ISIS), has shut down operations after the startup’s only drug candidate failed in a mid-stage clinical trial against asthma, Xconomy has learned.